

What is next?

Prior to scheduling your injection series, your insurance coverage needs to be verified. You may hear from the following who have been authorized by your Doctor's office to contact you:

- ORTHOVISLine
- Your specialty pharmacy (ex., Caremark, BioScript, Caremed)

Timely reply to their request will expedite your insurance benefit verification and allow your ORTHOVISC®/MONOVISC® High Molecular Weight Hyaluronan injection series to be scheduled.

To learn more about ORTHOVISC/MONOVISC, visit our website at: www.orthovisc.com or www.depuyssynthes.com

ORTHO**VISC**[®]
HIGH MOLECULAR WEIGHT HYALURONAN

MONO**VISC**[®]
High Molecular Weight Hyaluronan

Is your knee pain holding you back?

Your doctor has selected ORTHOVISC/MONOVISC as a next step in the management of your knee pain due to osteoarthritis.

ORTHOVISC/MONOVISC:

- RELIEVES knee pain and can provide up to 6 months of relief¹
- REPLACES natural joint fluid to cushion, protect and lubricate your knee
- Is administered in your doctor's office in 1,3 or 4 injections into your knee joint at the precise site of your pain
- Is an FDA approved non-drug therapy made from ultra-pure natural hyaluronan which is found in healthy knees



DePuy Synthes

MITEK SPORTS MEDICINE

People inspired™

DePuy Mitek, Inc.

325 Paramount Drive

Raynham, MA 02767

Tel: +1 (800) 382-4682

www.depuyorthosynthes.com

¹ORTHOVISC/MONOVISC manufacturer's full prescribing information

Information from package inserts.

ORTHOVISC® and MONOVISC® are registered trademarks of and are manufactured by Anika Therapeutics. ORTHOVISC®/MONOVISC® High Molecular Weight Hyaluronan are indicated for knee osteoarthritis.

Important Safety Information

High Molecular Weight Hyaluronan is indicated in the treatment of pain in osteoarthritis (OA) of the knee in patients who have failed to respond adequately to conservative nonpharmacologic therapy and to simple analgesics, e.g., acetaminophen. In clinical studies, the most commonly reported adverse events were arthralgia, back pain, and headache. In clinical studies, the most commonly reported adverse events for MONOVISC were arthralgia, joint swelling and injection site pain. ORTHOVISC and MONOVISC are contraindicated in patients with known hypersensitivity to hyaluronate formulations or known hypersensitivity (allergy) to gram positive bacterial proteins. ORTHOVISC and MONOVISC should not be injected in patients with infections or skin diseases in the area of the injection site or joint. MONOVISC should not be administered to patients with known bleeding disorders.